Pulse Biosciences (NASDAQ:PLSE) CTO Darrin Uecker Sells 25,000 Shares

Key Points

• Darrin Uecker, the CTO of Pulse Biosciences, sold 25,000 shares at an average price of $14.78, decreasing his ownership by 16.91% and retaining 122,872 shares valued at over $1.8 million.
• Pulse Biosciences' stock recently traded up 8.4%, reaching $15.74, with a twelve-month high of $25.00 and a market cap of approximately $1.06 billion.
• Analysts have issued a price target of $22.00 for Pulse Biosciences, with the stock receiving an average rating of "Buy" from investment analysts.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) CTO Darrin Uecker sold 25,000 shares of Pulse Biosciences stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $14.78, for a total value of $369,500.00. Following the transaction, the chief technology officer owned 122,872 shares of the company's stock, valued at approximately $1,816,048.16. This represents a 16.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Darrin Uecker also recently made the following trade(s):

• On Wednesday, September 17th, Darrin Uecker sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $16.21, for a total value of $324,200.00.
• On Monday, September 15th, Darrin Uecker sold 25,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $15.77, for a total value of $394,250.00.

Pulse Biosciences Price Performance

PLSE stock traded down $0.91 during trading on Friday, hitting $17.61. 523,812 shares of the company traded hands, compared to its average volume of 204,930. The company has a market cap of $1.19 billion, a PE ratio of -16.77 and a beta of 1.68. Pulse Biosciences, Inc has a 1 year low of $13.77 and a 1 year high of $25.00. The stock's 50-day simple moving average is $15.57 and its 200 day simple moving average is $16.15.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02).

Analysts Set New Price Targets

Separately, Oppenheimer started coverage on Pulse Biosciences in a research note on Monday, July 7th. They issued an "outperform" rating and a $22.00 price target on the stock. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Pulse Biosciences presently has a consensus rating of "Buy" and an average price target of $22.00.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after buying an additional 680 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after buying an additional 2,156 shares during the period. AlphaQuest LLC raised its holdings in shares of Pulse Biosciences by 68.0% in the 1st quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after buying an additional 1,261 shares during the period. PNC Financial Services Group Inc. purchased a new stake in shares of Pulse Biosciences in the 1st quarter valued at $90,000. Finally, GAMMA Investing LLC raised its holdings in shares of Pulse Biosciences by 2,203.1% in the 1st quarter. GAMMA Investing LLC now owns 6,034 shares of the company's stock valued at $97,000 after buying an additional 5,772 shares during the period. Hedge funds and other institutional investors own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.